• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

BioArctic

285.00 SEK

-3.06 %

Less than 1K followers

BIOA B

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-3.06 %
-10.26 %
-4.62 %
-8.30 %
-10.38 %
+41.65 %
-15.28 %
+163.89 %
+882.76 %

BioArctic is a biopharmaceutical company focused on developing new treatments that address the causes of neurodegenerative diseases. Examples of diseases include Alzheimer's and Parkinson's. A large part of the research is carried out in collaboration with researchers at universities and hospitals. BioArctic was founded in 2003 and is headquartered in Stockholm.

Read more
Market cap
25.29B SEK
Turnover
65.6M SEK
Revenue
2B
EBIT %
62.97 %
P/E
24.68
Dividend yield-%
0.7 %
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
ShowingAll content types

Forum discussions
If you are investing in a company whose goal is to find cures for diseases such as Alzheimer’s, Parkinson’s, and ALS, BioArctic is the right investment for you, as this company’s ambitions are certainly not lacking. In addition, there is evidence, as a drug called Lecanemab has actually...
8/28/2025, 10:21 AM
by Hawkmountdiver
7
About that valuation. What has been the share price development in recent years? A quick read suggests it looks good. If compared to Faron and Herantis companies, this is a safer investment target at this moment.
8/28/2025, 2:16 PM
by j.sälli
2
Brand new Q2 / 2025 below. bioarctic.com wkr0006-146.pdf 1682.08 KB
8/28/2025, 10:28 AM
by Hawkmountdiver
0
Read more on our forum
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26.8
2026

Interim report Q2'26

25.11
2026

Interim report Q3'26

17.2
2027

Annual report '26

Regulatory press release5/29/2026, 4:30 PM

Number of shares and votes in BioArctic AB (publ) as of May 29, 2026

BioArctic
Regulatory press release5/28/2026, 4:30 PM

Bulletin from the Annual General Meeting in BioArctic AB (publ)

BioArctic
Regulatory press release5/25/2026, 7:15 AM

BioArctic's partner Eisai presents sales simulation of potential future sales of Leqembi® at its Investor Relations Day

BioArctic

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
BioArctic, Audiocast, Q1'26
Webcast5/20/2026, 7:30 AM

BioArctic, Audiocast, Q1'26

BioArctic
Regulatory press release5/20/2026, 5:00 AM

Interim Report for the period January - March 2026

BioArctic
Press release5/15/2026, 11:30 AM

Modular Finance IR Consensus: BioArctic – Consensus estimates Q1 2026

BioArctic
Regulatory press release5/15/2026, 6:30 AM

Eisai projects Leqembi® revenue to total JPY 143.5 billion for fiscal year 2026 (April 2026 - March 2027)

BioArctic
Press release5/13/2026, 6:30 AM

Invitation to presentation of BioArctic's first quarter report for January - March 2026 on May 20 at 9:30 a.m. CET

BioArctic
Regulatory press release5/8/2026, 6:30 AM

BioArctic: Leqembi® Iqlik™ PDUFA date updated to August 24 in the U.S.

BioArctic
Regulatory press release4/29/2026, 10:00 AM

BioArctic: Leqembi® annual sales exceed EUR 500 million - second sales milestone achieved

BioArctic
Regulatory press release4/29/2026, 10:00 AM

BioArctic: Sales of Leqembi® totaled 26.2 billion yen in the first quarter 2026

BioArctic
Regulatory press release4/21/2026, 6:30 PM

Notice of Annual General Meeting 2026 in BioArctic AB (publ)

BioArctic
Regulatory press release4/21/2026, 6:00 PM

BioArctic publishes the Annual Report and Sustainability Report for 2025

BioArctic
Regulatory press release3/27/2026, 7:00 AM

The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB

BioArctic
Press release3/23/2026, 7:30 AM

BioArctic: New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress

BioArctic
Press release3/11/2026, 7:00 AM

BioArctic: Latest data on long-term, real-world treatment with lecanemab will be presented at the AD/PD™ 2026 congress

BioArctic
Regulatory press release2/27/2026, 5:30 PM

Number of shares and votes in BioArctic AB (publ) as of February 27, 2026

BioArctic
Press release2/24/2026, 9:27 AM

Redeye: BioArctic (Q4 review): High quality, high expectations

BioArctic
BioArctic, Audiocast, Q4'25
Webcast2/18/2026, 8:30 AM

BioArctic, Audiocast, Q4'25

BioArctic
Regulatory press release2/18/2026, 7:00 AM

BioArctic: Interim Report for the period October - December 2025

BioArctic